Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

NCT03168464 PHASE1, PHASE2 TERMINATED Results posted

NSCLC patients with metastatic disease who have failed at least one prior treatment and have a minimum of two metastatic lesions (at least one measurable), are eligible if they have an ECOG Performance Status of 0-1. Patients will receive on Day 1, ipilimumab (every 6 weeks) concurrently with radiation (6Gy x 5 fractions). Nivolumab (every 2 weeks) will be given in addition to ipilimumab on day 22.

Details

Lead sponsor	Weill Medical College of Cornell University
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	15
Start date	Mon Oct 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Mar 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non Small Cell Lung Cancer Metastatic

Interventions

• Ipilimumab
• Nivolumab
• Radiation therapy

Countries

United States